Lexicon Pharmaceuticals Statistics
Total Valuation
LXRX has a market cap or net worth of $184.40 million. The enterprise value is $49.66 million.
Important Dates
The next estimated earnings date is Thursday, May 1, 2025, after market close.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LXRX has 361.49 million shares outstanding. The number of shares has increased by 44.73% in one year.
| Current Share Class | 361.49M |
| Shares Outstanding | 361.49M |
| Shares Change (YoY) | +44.73% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.14% |
| Owned by Institutions (%) | 36.35% |
| Float | 182.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.15 |
| Forward PS | 10.63 |
| PB Ratio | 1.24 |
| P/TBV Ratio | 1.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.44, with a Debt / Equity ratio of 0.73.
| Current Ratio | 5.44 |
| Quick Ratio | 5.34 |
| Debt / Equity | 0.73 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.86 |
Financial Efficiency
Return on equity (ROE) is -167.66% and return on invested capital (ROIC) is -51.20%.
| Return on Equity (ROE) | -167.66% |
| Return on Assets (ROA) | -43.77% |
| Return on Invested Capital (ROIC) | -51.20% |
| Return on Capital Employed (ROCE) | -73.00% |
| Revenue Per Employee | $301,757 |
| Profits Per Employee | -$1.95M |
| Employee Count | 103 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 274.50 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.91% in the last 52 weeks. The beta is 1.03, so LXRX's price volatility has been similar to the market average.
| Beta (5Y) | 1.03 |
| 52-Week Price Change | -69.91% |
| 50-Day Moving Average | 0.51 |
| 200-Day Moving Average | 1.17 |
| Relative Strength Index (RSI) | 53.29 |
| Average Volume (20 Days) | 32,170,088 |
Short Selling Information
The latest short interest is 43.88 million, so 12.14% of the outstanding shares have been sold short.
| Short Interest | 43.88M |
| Short Previous Month | 39.26M |
| Short % of Shares Out | 12.14% |
| Short % of Float | 24.07% |
| Short Ratio (days to cover) | 1.41 |
Income Statement
In the last 12 months, LXRX had revenue of $31.08 million and -$200.40 million in losses. Loss per share was -$0.63.
| Revenue | 31.08M |
| Gross Profit | -52.92M |
| Operating Income | -184.82M |
| Pretax Income | n/a |
| Net Income | -200.40M |
| EBITDA | -184.28M |
| EBIT | -184.82M |
| Loss Per Share | -$0.63 |
Full Income StatementBalance Sheet
The company has $237.96 million in cash and $106.07 million in debt, giving a net cash position of $131.88 million or $0.36 per share.
| Cash & Cash Equivalents | 237.96M |
| Total Debt | 106.07M |
| Net Cash | 131.88M |
| Net Cash Per Share | $0.36 |
| Equity (Book Value) | 145.95M |
| Book Value Per Share | 0.40 |
| Working Capital | 200.95M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$178.78 million and capital expenditures -$1.03 million, giving a free cash flow of -$179.81 million.
| Operating Cash Flow | -178.78M |
| Capital Expenditures | -1.03M |
| Free Cash Flow | -179.81M |
| FCF Per Share | -$0.50 |
Full Cash Flow StatementMargins
| Gross Margin | -170.25% |
| Operating Margin | -594.63% |
| Pretax Margin | -644.78% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -44.73% |
| Shareholder Yield | -44.73% |
| Earnings Yield | -110.39% |
| FCF Yield | -99.05% |
Analyst Forecast
The average price target for LXRX is $3.67, which is 619.47% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.67 |
| Price Target Difference | 619.47% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 43.31% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on May 21, 2015. It was a reverse split with a ratio of 0.1428571:1.
| Last Split Date | May 21, 2015 |
| Split Type | Reverse |
| Split Ratio | 0.1428571:1 |
Scores
LXRX has an Altman Z-Score of -8.24 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.24 |
| Piotroski F-Score | 3 |